Compared with the low-CAPS group, the high-CAPS group had a pro-cancer immune microenvironment, low TMB, high TIDE score, and relatively poor anti-PD-1 and anti-CTLA4 therapeutic efficacy. The gene discussed is CTLA4; the disease is cancer.